Table of Contents:
Background: Differenciated thyroid cancer presents with a very favourable prognosis. However, there are some cases with differentiated thyroid cancer that are refractory to the established treatment consistant of thyroidectomy, radioactive 131-Iodide therapy and Thyrotropin-suppression. Chimeric antigen receptor T-cells (CART) have already shown impressive results in hematological cancers.
Objective: This study aims to evaluate the potential of CART targeting the Thyrotropin-receptor (anti-TSHR CART) against differentiated, TSHR-positive thyroid cancer.
Material and methods: Target cells are the papillary thyroid cancer cell line K-1 and the follicular thyroid cancer cell line FTC-133. The killing of target cells by anti-TSHR CART is measured as a reduction of target cells in co-culture un-der the microscope, the fluorescence microscope (after GFP-labelling) and with a caspase-3/7-luminescnece analysis.
Results: With K-1 cells we could detect a significant difference between anti-TSHR CART and unspecific CART (T-value = 0.01), while anti-TSHR CART in comparison to unmodified T cells just missed significance (T-value = 0.06). With FTC-133 cells we could detect a significant difference between anti-TSHR CART and unmodified T cells (T-value = 0.02), while anti-TSHR CART in com-parison to unspecific CART just missed significance (T-value = 0.06) (signifi-cance level α = 0.05).
Conclusion: Anti-TSHR CART pose a potentially new treatment option to ab-late healthy and malignant transformed thyroid cells expressing the Thyrotropin-receptor.